Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors

Investigational New Drugs

Volumn 29, Issue 3, 2011, Pages 473-480

  Hubbard, Joleen ^a   Erlichman, Charles ^a   Toft, David O ^b   Qin, Rui ^a   Stensgard, Bridget A ^b   Felten, Sara ^a   Ten Eyck, Cynthia ^a   Batzel, Gretchen ^a   Ivy, S Percy ^c   Haluska, Paul ^a  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

17 allyaminogeldanamycin; Cisplatin; Gemcitabine; Heat shock protein 70; Heat shock protein 90; ILK; Phase I

Indexed keywords

CISPLATIN; GEMCITABINE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; INTEGRIN LINKED KINASE; TANESPIMYCIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BILE DUCT CARCINOMA; BLADDER CANCER; BLOOD TOXICITY; BLURRED VISION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; COLON CANCER; CONSCIOUSNESS LEVEL; CONSTIPATION; COUGHING; DEHYDRATION; DESQUAMATION; DIARRHEA; DISEASE COURSE; DIZZINESS; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EDEMA; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HEMATEMESIS; HICCUP; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INFECTION; INVOLUNTARY MOVEMENT; KIDNEY CANCER; LEUKOPENIA; LUNG CANCER; LYMPHOCYTOPENIA; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROENDOCRINE TUMOR; NEUROLOGIC DISEASE; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIMARY PERITONEAL CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RASH; RECTUM HEMORRHAGE; RIGOR; SARCOMA; SIDE EFFECT; SINUS TACHYCARDIA; SKIN IRRITATION; SMELLING DISORDER; SOLID TUMOR; STOMATITIS; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; THYROID CANCER; UTERUS CANCER; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOQUINONES; CISPLATIN; COHORT STUDIES; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MALE; MIDDLE AGED; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79955603500     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9381-y     Document Type: Article

References (31)

1. Richter K, Buchner J (2001) Hsp90: chaperoning signal transduction. J Cell Physiol 188(3):281-290 (Pubitemid 32777169)
2. Pratt WB, Toft DO (2003) Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 228(2):111-133 (Pubitemid 36187918)
3. Goetz MP et al (2003) The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 14(8):1169-1176 (Pubitemid 37039035)
4. Grenert JP et al (1997) The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 272(38):23843-23850 (Pubitemid 27410964)
5. Whitesell L et al (1994) Inhibition of heat shock protein HSP90-pp 60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 91(18):8324-8328
6. Supko JG et al (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36(4):305-315
7. Schulte TW, Neckers LM (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42(4):273-279 (Pubitemid 28393843)
8. Goetz MP et al (2005) Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23(6):1078-1087 (Pubitemid 46202262)
9. Solit DB et al (2007) Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13(6):1775-1782 (Pubitemid 46952945)
10. Heath EI et al (2008) A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 14(23):7940-7946
11. Ronnen EA et al (2006) A phase II trial of 17-(Allylamino)-17- demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 24(6):543-546 (Pubitemid 44273031)
12. Abraham RT (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15(17):2177-2196
13. Zhou BB, Elledge SJ (2000) The DNA damage response: putting checkpoints in perspective. Nature 408(6811):433-439
14. Rhind N, Russell P (2000) Chk1 and Cds1: linchpins of the DNA damage and replication checkpoint pathways. J Cell Sci 113(Pt 22):3889-3896 (Pubitemid 32194514)
15. Zachos G, Rainey MD, Gillespie DA (2003) Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. Embo J 22(3):713-723 (Pubitemid 36193615)
16. Arlander SJ et al (2003) Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 278 (52):52572-52577 (Pubitemid 38035854)
17. McCollum AK et al (2008) Cisplatin abrogates the geldanamycin-induced heat shock response. Mol Cancer Ther 7(10):3256-3264
18. Nair SC et al (1996) A pathway of multi-chaperone interactions common to diverse regulatory proteins: estrogen receptor, Fes tyrosine kinase, heat shock transcription factor Hsf1, and the aryl hydrocarbon receptor. Cell Stress Chaperones 1(4):237-250
19. Kim HR, Kang HS, Kim HD (1999) Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells. IUBMB Life 48(4):429-433
20. Whitesell L, Bagatell R, Falsey R (2003) The stress response: implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets 3(5):349-358 (Pubitemid 37128321)
21. Winklhofer KF et al (2001) Geldanamycin restores a defective heat shock response in vivo. J Biol Chem 276(48):45160-45167
22. Bagatell R et al (2000) Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 6(8):3312-3318 (Pubitemid 30637762)
23. Nowakowski GS et al (2006) A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 12(20 Pt 1):6087-6093 (Pubitemid 44703773)
24. Ramanathan RK et al (2007) Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 13(6):1769-1774 (Pubitemid 46952944)
25. McCollum AK, Toft D, Erlichman C (2003) Geldanamycin enhances cisplain cytotoxicty through loss of Akt activation in A549 cells. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, pp 16
26. Aoyagi Y, Fujita N, Tsuruo T (2005) Stabilization of integrinlinked kinase by binding to Hsp90. Biochem Biophys Res Commun 331(4):1061-1068 (Pubitemid 40692468)
27. Kramer CY (1956) Extension of multiple range tests to group means with unequal numbers of replications. Biometrics 12:307-310
28. McCollum AK et al (2008) P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res 68(18):7419-7427
29. Modi S et al (2007) Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 25(34):5410-5417 (Pubitemid 350232217)
30. Richardson PG, Chanan-Khan A, Lonial S, et al (2007) Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings 25(18S):3532, June 20 Supplement
31. Tse AN et al (2008) A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res 14(20):6704-6711